Form 4: VolitionRX CFO Terig Hughes Receives Stock Award in Lieu of Cash Compensation

Terig Hughes, CFO of VolitionRX Ltd, received 13,493 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Summary

• On September 1, 2024, Terig Hughes, the Chief Financial Officer of VolitionRX Ltd, was granted 13,493 restricted stock units (RSUs).
• The RSUs were awarded under the Issuer's 2015 Stock Incentive Plan.
• These RSUs were given in place of cash compensation that would have otherwise been paid to Mr. Hughes.
• The RSUs vest in three installments: 4,498 units on September 1, 2024, 4,498 units on October 1, 2024, and 4,497 units on November 1, 2024.
• The RSUs are also subject to further time-based vesting in a single installment on June 1, 2025.
• Vesting is contingent upon continued service throughout each applicable vesting date.
• Upon vesting and settlement, Mr. Hughes will receive common stock equal to the number of RSUs that have vested.
• Following the transaction, Mr. Hughes beneficially owns 363,569 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The use of RSUs instead of cash could be seen as slightly positive for the company's cash flow, but it's not a major event.

Positives

• The award of RSUs to the CFO aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• Using RSUs instead of cash compensation can help the company conserve cash.

Risks

• The value of the RSUs is tied to the performance of VolitionRX's stock, which can be volatile.
• If Mr. Hughes leaves the company before the RSUs fully vest, he will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Stock-based compensation is a common practice in the biotechnology industry to attract and retain talent, especially in companies that may be cash-strapped or prioritizing investment in research and development.

Comparison to Industry Standards

• Granting RSUs in lieu of cash compensation is a fairly standard practice among smaller biotech companies to conserve cash.
• Comparable companies like Exact Sciences or Guardant Health also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedule described is typical, with vesting occurring over multiple periods to incentivize continued employment.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign that the CFO is incentivized to increase shareholder value.
• Employees may see the RSU grant as a sign that the company values its executives.

Key Dates